enGene (NASDAQ:ENGN) Earns Buy Rating from Analysts at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of enGene (NASDAQ:ENGN) in a research note released on Friday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $28.00 target price on the stock.

A number of other brokerages have also recently commented on ENGN. Citigroup reaffirmed a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Morgan Stanley upped their price target on enGene from $18.00 to $19.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of enGene in a research report on Friday, January 9th. HC Wainwright reissued a “buy” rating and issued a $25.00 target price on shares of enGene in a report on Wednesday, December 3rd. Finally, Raymond James Financial upgraded shares of enGene from an “outperform” rating to a “strong-buy” rating and set a $27.00 target price on the stock in a research note on Tuesday, November 11th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, enGene presently has a consensus rating of “Moderate Buy” and an average target price of $23.00.

enGene Stock Performance

ENGN opened at $9.53 on Friday. The company’s 50 day moving average is $8.89 and its 200 day moving average is $7.01. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.09. The company has a market cap of $638.41 million, a price-to-earnings ratio of -4.16 and a beta of -0.29. enGene has a 12-month low of $2.65 and a 12-month high of $12.25.

enGene (NASDAQ:ENGN) last announced its earnings results on Monday, December 22nd. The company reported ($0.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). On average, equities research analysts predict that enGene will post -1.56 EPS for the current year.

Institutional Investors Weigh In On enGene

Institutional investors and hedge funds have recently modified their holdings of the stock. Cresset Asset Management LLC bought a new position in shares of enGene during the second quarter worth $36,000. Paloma Partners Management Co purchased a new stake in enGene in the 2nd quarter worth $38,000. PFS Partners LLC bought a new position in shares of enGene during the 3rd quarter valued at about $61,000. Raymond James Financial Inc. boosted its holdings in shares of enGene by 383.6% during the 3rd quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares during the last quarter. Finally, Hudson Bay Capital Management LP purchased a new position in shares of enGene during the third quarter valued at about $76,000. Institutional investors own 64.16% of the company’s stock.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.